170 related articles for article (PubMed ID: 24135631)
1. A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.
Schubert I; Saul D; Nowecki S; Mackensen A; Fey GH; Oduncu FS
MAbs; 2014; 6(1):286-96. PubMed ID: 24135631
[TBL] [Abstract][Full Text] [Related]
2. A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.
Schubert I; Kellner C; Stein C; Kügler M; Schwenkert M; Saul D; Stockmeyer B; Berens C; Oduncu FS; Mackensen A; Fey GH
MAbs; 2012; 4(1):45-56. PubMed ID: 22327429
[TBL] [Abstract][Full Text] [Related]
3. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.
Schubert I; Kellner C; Stein C; Kügler M; Schwenkert M; Saul D; Mentz K; Singer H; Stockmeyer B; Hillen W; Mackensen A; Fey GH
MAbs; 2011; 3(1):21-30. PubMed ID: 21081841
[TBL] [Abstract][Full Text] [Related]
4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
5. Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.
Roskopf CC; Braciak TA; Fenn NC; Kobold S; Fey GH; Hopfner KP; Oduncu FS
Oncotarget; 2016 Apr; 7(16):22579-89. PubMed ID: 26981773
[TBL] [Abstract][Full Text] [Related]
6. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
[TBL] [Abstract][Full Text] [Related]
7. CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.
Schiller CB; Braciak TA; Fenn NC; Seidel UJ; Roskopf CC; Wildenhain S; Honegger A; Schubert IA; Schele A; Lämmermann K; Fey GH; Jacob U; Lang P; Hopfner KP; Oduncu FS
Oncotarget; 2016 Dec; 7(50):83392-83408. PubMed ID: 27825135
[TBL] [Abstract][Full Text] [Related]
8. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.
Kügler M; Stein C; Kellner C; Mentz K; Saul D; Schwenkert M; Schubert I; Singer H; Oduncu F; Stockmeyer B; Mackensen A; Fey GH
Br J Haematol; 2010 Sep; 150(5):574-86. PubMed ID: 20636437
[TBL] [Abstract][Full Text] [Related]
9. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
10. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells.
Stein C; Kellner C; Kügler M; Reiff N; Mentz K; Schwenkert M; Stockmeyer B; Mackensen A; Fey GH
Br J Haematol; 2010 Mar; 148(6):879-89. PubMed ID: 20064159
[TBL] [Abstract][Full Text] [Related]
11. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
12. T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell.
Roskopf CC; Schiller CB; Braciak TA; Kobold S; Schubert IA; Fey GH; Hopfner KP; Oduncu FS
Oncotarget; 2014 Aug; 5(15):6466-83. PubMed ID: 25115385
[TBL] [Abstract][Full Text] [Related]
13. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.
Bruenke J; Fischer B; Barbin K; Schreiter K; Wachter Y; Mahr K; Titgemeyer F; Niederweis M; Peipp M; Zunino SJ; Repp R; Valerius T; Fey GH
Br J Haematol; 2004 Apr; 125(2):167-79. PubMed ID: 15059139
[TBL] [Abstract][Full Text] [Related]
14. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells.
Kellner C; Bruenke J; Horner H; Schubert J; Schwenkert M; Mentz K; Barbin K; Stein C; Peipp M; Stockmeyer B; Fey GH
Cancer Lett; 2011 Apr; 303(2):128-39. PubMed ID: 21339041
[TBL] [Abstract][Full Text] [Related]
15. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
16. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
[TBL] [Abstract][Full Text] [Related]
17. Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes.
Costa-García M; Ataya M; Moraru M; Vilches C; López-Botet M; Muntasell A
Front Immunol; 2019; 10():687. PubMed ID: 31001281
[TBL] [Abstract][Full Text] [Related]
18. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis.
Xie Z; Guo N; Yu M; Hu M; Shen B
J Immunol Methods; 2005 Jan; 296(1-2):95-101. PubMed ID: 15680154
[TBL] [Abstract][Full Text] [Related]
19. NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2.
Braciak TA; Wildenhain S; Roskopf CC; Schubert IA; Fey GH; Jacob U; Hopfner KP; Oduncu FS
J Transl Med; 2013 Nov; 11():289. PubMed ID: 24237598
[TBL] [Abstract][Full Text] [Related]
20. Natural killer-mediated lysis of some but not all HSV-1- or VSV-infected targets requires the participation of HLA-DR-positive accessory cells.
Howell DM; Fitzgerald-Bocarsly P
Immunology; 1991 Mar; 72(3):443-7. PubMed ID: 1851136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
